JPWO2020146440A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146440A5 JPWO2020146440A5 JP2021539935A JP2021539935A JPWO2020146440A5 JP WO2020146440 A5 JPWO2020146440 A5 JP WO2020146440A5 JP 2021539935 A JP2021539935 A JP 2021539935A JP 2021539935 A JP2021539935 A JP 2021539935A JP WO2020146440 A5 JPWO2020146440 A5 JP WO2020146440A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- active agent
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 claims description 22
- 208000034578 Multiple myelomas Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 229940125782 compound 2 Drugs 0.000 claims description 5
- 229940125904 compound 1 Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 61
- 239000003112 inhibitor Substances 0.000 claims 47
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 7
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 claims 7
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 7
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 229940124291 BTK inhibitor Drugs 0.000 claims 5
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims 5
- 229940124647 MEK inhibitor Drugs 0.000 claims 5
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 claims 5
- 229940124302 mTOR inhibitor Drugs 0.000 claims 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 5
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 5
- 229960004066 trametinib Drugs 0.000 claims 5
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 5
- 102100032306 Aurora kinase B Human genes 0.000 claims 4
- 108091005625 BRD4 Proteins 0.000 claims 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 4
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims 4
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 4
- 102100029095 Exportin-1 Human genes 0.000 claims 4
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 claims 4
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 claims 4
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims 4
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 claims 4
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 4
- 108010002687 Survivin Proteins 0.000 claims 4
- 101150094313 XPO1 gene Proteins 0.000 claims 4
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 4
- 108700002148 exportin 1 Proteins 0.000 claims 4
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 4
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 4
- 229950004774 tazemetostat Drugs 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- VRQXRVAKPDCRCI-ZNMIVQPWSA-N n-[4-[(1r,3s,5s)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide Chemical group C1[C@H](C)C[C@H](N)C[C@@H]1C1=CC=NC=C1NC(=O)C1=CC=C(F)C(C=2C(=CC=CC=2F)F)=N1 VRQXRVAKPDCRCI-ZNMIVQPWSA-N 0.000 claims 3
- 229960001308 trametinib dimethyl sulfoxide Drugs 0.000 claims 3
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical compound CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 claims 3
- IQCKJUKAQJINMK-HUBRGWSESA-N 1-[3-[[(2r,3s,4r,5r)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea Chemical group C([C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2C(Br)=C1)O)N(C(C)C)CCCNC(=O)NC1=CC=C(C(C)(C)C)C=C1 IQCKJUKAQJINMK-HUBRGWSESA-N 0.000 claims 2
- LXFOLMYKSYSZQS-LURJZOHASA-N CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1 Chemical compound CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1 LXFOLMYKSYSZQS-LURJZOHASA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 2
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical group N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 claims 2
- 229950003487 fedratinib Drugs 0.000 claims 2
- 229960001507 ibrutinib Drugs 0.000 claims 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 2
- HPODOLXTMDHLLC-QGZVFWFLSA-N n-[(4-methoxy-6-methyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-1-[(1r)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C3=CC=CC=C3N([C@H](C)C3CCN(CC(F)(F)F)CC3)C=2C)=C1OC HPODOLXTMDHLLC-QGZVFWFLSA-N 0.000 claims 2
- DPJNKUOXBZSZAI-UHFFFAOYSA-N n-[(6-methyl-2-oxo-4-propyl-1h-pyridin-3-yl)methyl]-1-propan-2-yl-6-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]indazole-4-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=NC(=CC=2)N2CCN(CC2)C(C)C)C(C)C)=C1CCC DPJNKUOXBZSZAI-UHFFFAOYSA-N 0.000 claims 2
- 229950006101 pinometostat Drugs 0.000 claims 2
- LMXOHSDXUQEUSF-YECHIGJVSA-N sinefungin Chemical compound O[C@@H]1[C@H](O)[C@@H](C[C@H](CC[C@H](N)C(O)=O)N)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LMXOHSDXUQEUSF-YECHIGJVSA-N 0.000 claims 2
- MCUJKPPARUPFJM-UWCCDQBKSA-N (5z)-5-[[2-[(3r)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1[C@H](N)CCCN1C(C(=CC=C1)C=2C=CC=CC=2)=C1\C=C/1C(=O)NC(=O)S\1 MCUJKPPARUPFJM-UWCCDQBKSA-N 0.000 claims 1
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 claims 1
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 claims 1
- OMKHWTRUYNAGFG-IEBDPFPHSA-N 3-deazaneplanocin a Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O OMKHWTRUYNAGFG-IEBDPFPHSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- PFHDWRIVDDIFRP-UHFFFAOYSA-N 6-cyano-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-1-pentan-3-ylindole-4-carboxamide Chemical compound C1=C(C#N)C=C2N(C(CC)CC)C=CC2=C1C(=O)NCC1=C(C)C=C(C)NC1=O PFHDWRIVDDIFRP-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 claims 1
- XRNVABDYQLHODA-JCNLHEQBSA-N CC(C)(O)[C@H]1CC[C@@H](CC1)NC1=NN2C(C=C1)=NC=C2C1=CC=CC(=C1)C(F)(F)F Chemical compound CC(C)(O)[C@H]1CC[C@@H](CC1)NC1=NN2C(C=C1)=NC=C2C1=CC=CC(=C1)C(F)(F)F XRNVABDYQLHODA-JCNLHEQBSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 claims 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 1
- MHXGEROHKGDZGO-UHFFFAOYSA-N N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-6-imidazo[1,2-b]pyridazinamine Chemical compound C1CN(C)CCC1CNC1=NN2C(C=3C=C(OC(F)(F)F)C=CC=3)=CN=C2C=C1 MHXGEROHKGDZGO-UHFFFAOYSA-N 0.000 claims 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 claims 1
- 229950009821 acalabrutinib Drugs 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 229950000971 baricitinib Drugs 0.000 claims 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims 1
- 229950003054 binimetinib Drugs 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002271 cobimetinib Drugs 0.000 claims 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229950008908 gandotinib Drugs 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229950001845 lestaurtinib Drugs 0.000 claims 1
- -1 or a stereoisomer Substances 0.000 claims 1
- 229950011410 pacritinib Drugs 0.000 claims 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960000215 ruxolitinib Drugs 0.000 claims 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 1
- 229950010746 selumetinib Drugs 0.000 claims 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims 1
- 229950008974 sinefungin Drugs 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
Description
ある特定の実施形態では、本明細書に記載の化合物1、化合物2または化合物3及び本明細書に記載の第2の活性薬剤は、様々な種類またはステージの多発性骨髄腫の患者に、キメラ抗原受容体(CAR)T細胞と組み合わせて投与される。ある特定の実施形態では、組み合わせにおけるCAR T細胞は、B細胞成熟抗原(BCMA)を標的とし、より特定の実施形態では、CAR T細胞は、bb2121またはbb21217である。いくつかの実施形態では、CAR T細胞は、JCARH125である。 In certain embodiments, Compound 1, Compound 2 or Compound 3 as described herein and a second active agent as described herein are administered to patients with multiple myeloma of various types or stages as chimeric It is administered in combination with antigen receptor (CAR) T cells. In certain embodiments, the CAR T cells in the combination target B cell maturation antigen (BCMA), and in more particular embodiments, the CAR T cells are bb2121 or bb21217. In some embodiments, the CAR T cell is JCARH125.
Claims (54)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962790326P | 2019-01-09 | 2019-01-09 | |
US62/790,326 | 2019-01-09 | ||
PCT/US2020/012647 WO2020146440A1 (en) | 2019-01-09 | 2020-01-08 | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022516974A JP2022516974A (en) | 2022-03-03 |
JPWO2020146440A5 true JPWO2020146440A5 (en) | 2023-01-24 |
JP7467479B2 JP7467479B2 (en) | 2024-04-15 |
Family
ID=69500830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021539935A Active JP7467479B2 (en) | 2019-01-09 | 2020-01-08 | Antiproliferative compounds and second active agents and methods of combination use thereof in the treatment of multiple myeloma - Patents.com |
Country Status (13)
Country | Link |
---|---|
US (2) | US11660297B2 (en) |
EP (1) | EP3908281A1 (en) |
JP (1) | JP7467479B2 (en) |
KR (1) | KR20210126011A (en) |
CN (2) | CN114404596A (en) |
AU (1) | AU2020205643A1 (en) |
BR (1) | BR112021013290A2 (en) |
CA (1) | CA3125753A1 (en) |
EA (1) | EA202191903A1 (en) |
IL (1) | IL284671A (en) |
MX (1) | MX2021008294A (en) |
SG (1) | SG11202107413YA (en) |
WO (1) | WO2020146440A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117838695A (en) * | 2018-04-13 | 2024-04-09 | 住友制药肿瘤公司 | PIM kinase inhibitors for the treatment of myeloproliferative neoplasms and cancer-related fibrosis |
BR112021013383A2 (en) * | 2019-01-09 | 2021-09-14 | Celgene Corporation | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1- IL)-3-FLUOROBENZONITRILE AND METHODS FOR USING THEM |
CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2022251441A1 (en) | 2021-05-27 | 2022-12-01 | Celgene Corporation | Methods of treating multiple myeloma using combination therapy |
CA3226662A1 (en) * | 2021-07-12 | 2023-01-19 | Quteba Ebrahem | A method of treating cancer or a blood disorder |
CN117045800A (en) * | 2022-05-06 | 2023-11-14 | 上海科技大学 | Application of mTOR inhibitor in enhancing efficacy of targeted protein degradation drug |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
CN101899114A (en) | 2002-12-23 | 2010-12-01 | 惠氏公司 | Anti-PD-1 antibody and uses thereof |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CN104356236B (en) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
PE20120341A1 (en) | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
RS58523B1 (en) | 2010-02-11 | 2019-04-30 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
MX2017001656A (en) | 2014-08-08 | 2017-07-24 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof. |
CA2956962A1 (en) | 2014-08-13 | 2016-02-18 | Epizyme, Inc. | Combination therapy for treating cancer |
EP4201399A3 (en) * | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
JP7258009B2 (en) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | Antiproliferative compounds and methods of use thereof |
-
2020
- 2020-01-08 CN CN202210009586.2A patent/CN114404596A/en active Pending
- 2020-01-08 AU AU2020205643A patent/AU2020205643A1/en active Pending
- 2020-01-08 KR KR1020217025057A patent/KR20210126011A/en active Search and Examination
- 2020-01-08 CA CA3125753A patent/CA3125753A1/en active Pending
- 2020-01-08 JP JP2021539935A patent/JP7467479B2/en active Active
- 2020-01-08 US US16/737,710 patent/US11660297B2/en active Active
- 2020-01-08 MX MX2021008294A patent/MX2021008294A/en unknown
- 2020-01-08 CN CN202080018980.1A patent/CN113543786A/en active Pending
- 2020-01-08 SG SG11202107413YA patent/SG11202107413YA/en unknown
- 2020-01-08 BR BR112021013290-2A patent/BR112021013290A2/en active Search and Examination
- 2020-01-08 EP EP20704117.9A patent/EP3908281A1/en active Pending
- 2020-01-08 EA EA202191903A patent/EA202191903A1/en unknown
- 2020-01-08 WO PCT/US2020/012647 patent/WO2020146440A1/en unknown
-
2021
- 2021-07-07 IL IL284671A patent/IL284671A/en unknown
-
2023
- 2023-04-25 US US18/139,151 patent/US20230330086A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2521672T3 (en) | Pharmaceutical formulations for cancer treatment | |
KR20180113976A (en) | Concurrent therapy of tetracycline quinolone analogs to treat cancer | |
US20200171061A1 (en) | Methods for Cancer Therapy | |
US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
RU2019138222A (en) | APPLICATION OF EZH2 INHIBITOR IN COMBINATION WITH BTK INHIBITOR IN PREPARATION OF A DRUG FOR TREATMENT OF TUMOR | |
JP2018525411A (en) | BTK inhibitor combination for treating multiple myeloma | |
JP2023538520A (en) | Advantageous treatments for disorders mediated by IKAROS or AIOLOS | |
US20200197334A1 (en) | Paediatric Compositions For Treating Multiple Sclerosis | |
JP2023515817A (en) | A triple drug combination containing dabrafenib, an ERK inhibitor and a SHP2 inhibitor | |
JPWO2020146440A5 (en) | ||
JP2001512462A (en) | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy for the treatment of hepatitis virus infection | |
BG65472B1 (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce a medicament used in the treatment or prevention of serious depression disorders | |
EP2162129B1 (en) | Use of hdac inhibitors for the treatment of bone destruction | |
US20210379074A1 (en) | Combination therapy for treatment of myeloproliferative neoplasms | |
JP2011512383A (en) | Combination of iron chelator and immunosuppressant and use thereof | |
RU2006126828A (en) | NK-1 NEUROKININ RECEPTOR ANTAGONISTS FOR EXITING ANNEASIS | |
WO2021048419A1 (en) | Combination therapies comprising trametinib for the treatment of cholangiocarcinoma | |
WO2021180338A1 (en) | Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant | |
JP2013512195A5 (en) | ||
BR112020016389A2 (en) | USE OF 5-FLUOR-4- (4-FLUOR-2-METOXYPHENYL) -N- {4 - [(S-METHYLSULFONIMIDOIL) METHIL] PIRIDIN-2-IL} PIRIDIN-2-AMINE FOR TREATMENT OF DIFFUSED B-CELL LYMPHOMA BIG ONES | |
JPWO2021007245A5 (en) | ||
AU2021401681A1 (en) | Dosing of fedratinib | |
JP2018509439A (en) | 4- (4-Fluoro-2-methoxyphenyl) -N- {3-[(S-methylsulfonimidoyl) methyl] phenyl} -1,3,5-triazine-2 for the treatment of multiple myeloma -Use of amines | |
WO2002045715A1 (en) | Nootropic effect enhancer | |
AU2021200647A1 (en) | Paediatric compositions for treating multiple sclerosis |